{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T15:16:00Z","timestamp":1794582960610,"version":"4.9.1"},"reference-count":87,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,30]],"date-time":"2022-05-30T00:00:00Z","timestamp":1653868800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,30]],"date-time":"2022-05-30T00:00:00Z","timestamp":1653868800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP1089404"],"award-info":[{"award-number":["APP1089404"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1139071"],"award-info":[{"award-number":["1139071"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP1108638"],"award-info":[{"award-number":["APP1108638"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Australian Government Research Training Program","award":["na"],"award-info":[{"award-number":["na"]}]},{"DOI":"10.13039\/100013103","name":"QIMR Berghofer Medical Research Institute","doi-asserted-by":"publisher","award":["na"],"award-info":[{"award-number":["na"]}],"id":[{"id":"10.13039\/100013103","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001047","name":"Ian Potter Foundation","doi-asserted-by":"publisher","award":["na"],"award-info":[{"award-number":["na"]}],"id":[{"id":"10.13039\/501100001047","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The John Thomas Wilson Endowment","award":["na"],"award-info":[{"award-number":["na"]}]},{"name":"Estate of Mr Stewart Coggins","award":["na"],"award-info":[{"award-number":["na"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Genome Med"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Malignant pleural mesothelioma (MPM) has a poor overall survival with few treatment options. Whole genome sequencing (WGS) combined with the immune features of MPM offers the prospect of identifying changes that could inform future clinical trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analysed somatic mutations from 229 MPM samples, including previously published data and 58 samples that had undergone WGS within this study. This was combined with RNA-seq analysis to characterize the tumour immune environment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The comprehensive genome analysis identified 12 driver genes, including new candidate genes. Whole genome doubling was a frequent event that correlated with shorter survival. Mutational signature analysis revealed SBS5\/40 were dominant in 93% of samples, and defects in homologous recombination repair were infrequent in our cohort. The tumour immune environment contained high M2 macrophage infiltrate linked with\n                      <jats:italic>MMP2<\/jats:italic>\n                      ,\n                      <jats:italic>MMP14<\/jats:italic>\n                      ,\n                      <jats:italic>TGFB1<\/jats:italic>\n                      and\n                      <jats:italic>CCL2<\/jats:italic>\n                      expression, representing an immune suppressive environment. The expression of\n                      <jats:italic>TGFB1<\/jats:italic>\n                      was associated with overall survival. A small subset of samples (less than 10%) had a higher proportion of CD8 T cells and a high cytolytic score, suggesting a \u2018hot\u2019 immune environment independent of the somatic mutations.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>We propose accounting for genomic and immune microenvironment status may influence therapeutic planning in the future.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13073-022-01060-8","type":"journal-article","created":{"date-parts":[[2022,5,30]],"date-time":"2022-05-30T03:02:56Z","timestamp":1653879776000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Comprehensive genomic and tumour immune profiling reveals potential therapeutic targets in malignant pleural mesothelioma"],"prefix":"10.1186","volume":"14","author":[{"given":"Jenette","family":"Creaney","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann-Marie","family":"Patch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkateswar","family":"Addala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie A.","family":"Sneddon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katia","family":"Nones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian M.","family":"Dick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y. C. Gary","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felicity","family":"Newell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ebony J.","family":"Rouse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjan M.","family":"Naeini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Kondrashova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Lakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apostolos","family":"Nakas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Waller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annabel","family":"Sharkey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Mukhopadhyay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen H.","family":"Kazakoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lambros T.","family":"Koufariotis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimee L.","family":"Davidson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya","family":"Ramarao-Milne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Holmes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinying","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conrad","family":"Leonard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean M.","family":"Grimmond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Bueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean A.","family":"Fennell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John V.","family":"Pearson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7865-2760","authenticated-orcid":false,"given":"Bruce W.","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3950-2476","authenticated-orcid":false,"given":"Nicola","family":"Waddell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,30]]},"reference":[{"key":"1060_CR1","first-page":"260","volume":"17","author":"JC Wagner","year":"1960","unstructured":"Wagner JC, Sleggs CA, Marchand P. Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br J Ind Med. 1960;17:260\u201371.","journal-title":"Br J Ind Med"},{"issue":"3","key":"1060_CR2","doi-asserted-by":"publisher","first-page":"379","DOI":"10.2486\/indhealth.45.379","volume":"45","author":"C Bianchi","year":"2007","unstructured":"Bianchi C, Bianchi T. Malignant mesothelioma: global incidence and relationship with asbestos. Ind Health. 2007;45(3):379\u201387.","journal-title":"Ind Health"},{"issue":"4","key":"1060_CR3","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/ng.3520","volume":"48","author":"R Bueno","year":"2016","unstructured":"Bueno R, Stawiski EW, Goldstein LD, Durinck S, De Rienzo A, Modrusan Z, et al. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat Genet. 2016;48(4):407\u201316.","journal-title":"Nat Genet"},{"issue":"12","key":"1060_CR4","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1158\/2159-8290.CD-18-0804","volume":"8","author":"J Hmeljak","year":"2018","unstructured":"Hmeljak J, Sanchez-Vega F, Hoadley KA, Shih J, Stewart C, Heiman D, et al. Integrative molecular characterization of malignant pleural mesothelioma. Cancer Discov. 2018;8(12):1548\u201365.","journal-title":"Cancer Discov"},{"issue":"2","key":"1060_CR5","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1158\/0008-5472.CAN-14-1008","volume":"75","author":"G Guo","year":"2015","unstructured":"Guo G, Chmielecki J, Goparaju C, Heguy A, Dolgalev I, Carbone M, et al. Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma. Cancer Res. 2015;75(2):264\u20139.","journal-title":"Cancer Res"},{"key":"1060_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.102091","volume":"90","author":"BH Louie","year":"2020","unstructured":"Louie BH, Kurzrock R. BAP1: Not just a BRCA1-associated protein. Cancer Treat Rev. 2020;90:102091.","journal-title":"Cancer Treat Rev"},{"issue":"10272","key":"1060_CR7","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","volume":"397","author":"P Baas","year":"2021","unstructured":"Baas P, Scherpereel A, Nowak AK, Fujimoto N, Peters S, Tsao AS, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021;397(10272):375\u201386.","journal-title":"Lancet."},{"issue":"1","key":"1060_CR8","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1186\/s13063-018-2602-y","volume":"19","author":"DA Fennell","year":"2018","unstructured":"Fennell DA, Kirkpatrick E, Cozens K, Nye M, Lester J, Hanna G, et al. CONFIRM: a double-blind, placebo-controlled phase III clinical trial investigating the effect of nivolumab in patients with relapsed mesothelioma: study protocol for a randomised controlled trial. Trials. 2018;19(1):233.","journal-title":"Trials."},{"issue":"9","key":"1060_CR9","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1016\/S1470-2045(20)30462-9","volume":"21","author":"AK Nowak","year":"2020","unstructured":"Nowak AK, Lesterhuis WJ, Kok PS, Brown C, Hughes BG, Karikios DJ, et al. Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in. Lancet Oncol. 2020;21(9):1213\u201323.","journal-title":"Lancet Oncol"},{"issue":"1","key":"1060_CR10","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1093\/annonc\/mdy495","volume":"30","author":"TA Chan","year":"2019","unstructured":"Chan TA, Yarchoan M, Jaffee E, Swanton C, Quezada SA, Stenzinger A, et al. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Ann Oncol. 2019;30(1):44\u201356.","journal-title":"Ann Oncol"},{"issue":"3","key":"1060_CR11","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.cell.2021.01.002","volume":"184","author":"K Litchfield","year":"2021","unstructured":"Litchfield K, Reading JL, Puttick C, Thakkar K, Abbosh C, Bentham R, et al. Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition. Cell. 2021;184(3):596\u2013614 e14.","journal-title":"Cell."},{"issue":"2","key":"1060_CR12","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","volume":"51","author":"RM Samstein","year":"2019","unstructured":"Samstein RM, Lee CH, Shoushtari AN, Hellmann MD, Shen R, Janjigian YY, et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet. 2019;51(2):202\u20136.","journal-title":"Nat Genet"},{"issue":"1","key":"1060_CR13","doi-asserted-by":"publisher","first-page":"3292","DOI":"10.1038\/s41467-018-05228-y","volume":"9","author":"J Ma","year":"2018","unstructured":"Ma J, Setton J, Lee NY, Riaz N, Powell SN. The therapeutic significance of mutational signatures from DNA repair deficiency in cancer. Nat Commun. 2018;9(1):3292.","journal-title":"Nat Commun"},{"issue":"1","key":"1060_CR14","doi-asserted-by":"publisher","first-page":"1684713","DOI":"10.1080\/2162402X.2019.1684713","volume":"9","author":"S Sneddon","year":"2020","unstructured":"Sneddon S, Rive CM, Ma S, Dick IM, Allcock RJN, Brown SD, et al. Identification of a CD8+ T-cell response to a predicted neoantigen in malignant mesothelioma. Oncoimmunology. 2020;9(1):1684713.","journal-title":"Oncoimmunology."},{"issue":"9","key":"1060_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0045835","volume":"7","author":"S Song","year":"2012","unstructured":"Song S, Nones K, Miller D, Harliwong I, Kassahn KS, Pinese M, et al. qpure: a tool to estimate tumor cellularity from genome-wide single-nucleotide polymorphism profiles. PLoS One. 2012;7(9):e45835.","journal-title":"PLoS One"},{"issue":"1","key":"1060_CR16","first-page":"10","volume":"17","author":"M Martin","year":"2011","unstructured":"Martin M. Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnetjournal. 2011;17(1):10\u20132.","journal-title":"EMBnetjournal."},{"key":"1060_CR17","unstructured":"Li H. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. ArXiv. 2013; arXiv:1303.3997v2"},{"issue":"16","key":"1060_CR18","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1093\/bioinformatics\/btp352","volume":"25","author":"H Li","year":"2009","unstructured":"Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al. The sequence alignment\/map format and SAMtools. Bioinformatics. 2009;25(16):2078\u20139.","journal-title":"Bioinformatics."},{"key":"1060_CR19","unstructured":"Holmes O, Xu Q, Leonard C, Newell F, Wood S, Waddell N, Pearson JV. qcoverage. Github. https:\/\/github.com\/AdamaJava\/adamajava\/tree\/master\/qcoverage. Cited 13 May 2022."},{"issue":"11","key":"1060_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0074380","volume":"8","author":"KS Kassahn","year":"2013","unstructured":"Kassahn KS, Holmes O, Nones K, Patch AM, Miller DK, Christ AN, et al. Somatic point mutation calling in low cellularity tumors. PLoS One. 2013;8(11):e74380.","journal-title":"PLoS One"},{"issue":"9","key":"1060_CR21","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1101\/gr.107524.110","volume":"20","author":"A McKenna","year":"2010","unstructured":"McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010;20(9):1297\u2013303.","journal-title":"Genome Res"},{"issue":"1","key":"1060_CR22","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1038\/s41467-019-11107-x","volume":"10","author":"F Newell","year":"2019","unstructured":"Newell F, Kong Y, Wilmott JS, Johansson PA, Ferguson PM, Cui C, et al. Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets. Nat Commun. 2019;10(1):3163.","journal-title":"Nat Commun"},{"issue":"7553","key":"1060_CR23","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/nature14410","volume":"521","author":"AM Patch","year":"2015","unstructured":"Patch AM, Christie EL, Etemadmoghadam D, Garsed DW, George J, Fereday S, et al. Whole-genome characterization of chemoresistant ovarian cancer. Nature. 2015;521(7553):489\u201394.","journal-title":"Nature."},{"key":"1060_CR24","doi-asserted-by":"publisher","first-page":"15.9.1","DOI":"10.1002\/cpbi.17","volume":"56","author":"KM Raine","year":"2016","unstructured":"Raine KM, Van Loo P, Wedge DC, Jones D, Menzies A, Butler AP, et al. ascatNgs: identifying somatically acquired copy-number alterations from whole-genome sequencing data. Curr Protoc Bioinformatics. 2016;56:15.9.1\u201315.9.17.","journal-title":"Curr Protoc Bioinformatics"},{"issue":"4","key":"1060_CR25","doi-asserted-by":"publisher","first-page":"R41","DOI":"10.1186\/gb-2011-12-4-r41","volume":"12","author":"CH Mermel","year":"2011","unstructured":"Mermel CH, Schumacher SE, Hill B, Meyerson ML, Beroukhim R, Getz G. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 2011;12(4):R41.","journal-title":"Genome Biol"},{"issue":"1","key":"1060_CR26","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s13059-016-0994-0","volume":"17","author":"L Mularoni","year":"2016","unstructured":"Mularoni L, Sabarinathan R, Deu-Pons J, Gonzalez-Perez A, Lopez-Bigas N. OncodriveFML: a general framework to identify coding and non-coding regions with cancer driver mutations. Genome Biol. 2016;17(1):128.","journal-title":"Genome Biol"},{"issue":"2","key":"1060_CR27","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1038\/s41588-019-0572-y","volume":"52","author":"F Dietlein","year":"2020","unstructured":"Dietlein F, Weghorn D, Taylor-Weiner A, Richters A, Reardon B, Liu D, et al. Identification of cancer driver genes based on nucleotide context. Nat Genet. 2020;52(2):208\u201318.","journal-title":"Nat Genet"},{"issue":"7484","key":"1060_CR28","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nature12912","volume":"505","author":"MS Lawrence","year":"2014","unstructured":"Lawrence MS, Stojanov P, Mermel CH, Robinson JT, Garraway LA, Golub TR, et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature. 2014;505(7484):495\u2013501.","journal-title":"Nature."},{"issue":"3","key":"1060_CR29","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1159\/000507373","volume":"87","author":"NC Campanella","year":"2020","unstructured":"Campanella NC, Silva EC, Dix G, de Lima VF, Escremim de Paula F, Berardinelli GN, et al. Mutational profiling of driver tumor suppressor and oncogenic genes in Brazilian malignant pleural mesotheliomas. Pathobiology. 2020;87(3):208\u201316.","journal-title":"Pathobiology."},{"issue":"14","key":"1060_CR30","doi-asserted-by":"publisher","first-page":"3819","DOI":"10.1158\/1078-0432.CCR-19-3573","volume":"26","author":"C Pirker","year":"2020","unstructured":"Pirker C, Bilecz A, Grusch M, Mohr T, Heidenreich B, Laszlo V, et al. Telomerase reverse transcriptase promoter mutations identify a genomically defined and highly aggressive human pleural mesothelioma subgroup. Clin Cancer Res. 2020;26(14):3819\u201330.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1060_CR31","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.jmoldx.2015.07.010","volume":"18","author":"F Egberts","year":"2016","unstructured":"Egberts F, Bohne AS, Kruger S, Hedderich J, Rompel R, Haag J, et al. Varying mutational alterations in multiple primary melanomas. J Mol Diagn. 2016;18(1):75\u201383.","journal-title":"J Mol Diagn"},{"issue":"7653","key":"1060_CR32","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/nature22071","volume":"545","author":"NK Hayward","year":"2017","unstructured":"Hayward NK, Wilmott JS, Waddell N, Johansson PA, Field MA, Nones K, et al. Whole-genome landscapes of major melanoma subtypes. Nature. 2017;545(7653):175\u201380.","journal-title":"Nature."},{"key":"1060_CR33","doi-asserted-by":"crossref","unstructured":"Holmes O, Nones K, Tang YH, Loffler KA, Lee M, Patch AM, et al. qmotif: determination of telomere content from whole-genome sequence data. Bioinform Adv. 2022;2(1) Available from: https:\/\/github.com\/AdamaJava\/adamajava\/tree\/master\/qmotif. Cited 13 May 2022.","DOI":"10.1093\/bioadv\/vbac005"},{"issue":"D1","key":"1060_CR34","doi-asserted-by":"publisher","first-page":"D941","DOI":"10.1093\/nar\/gky1015","volume":"47","author":"JG Tate","year":"2019","unstructured":"Tate JG, Bamford S, Jubb HC, Sondka Z, Beare DM, Bindal N, et al. COSMIC: the catalogue of somatic mutations in cancer. Nucleic Acids Res. 2019;47(D1):D941\u2013D7.","journal-title":"Nucleic Acids Res"},{"issue":"5","key":"1060_CR35","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1002\/gcc.22918","volume":"60","author":"D Hubschmann","year":"2021","unstructured":"Hubschmann D, Jopp-Saile L, Andresen C, Kramer S, Gu Z, Heilig CE, et al. Analysis of mutational signatures with yet another package for signature analysis. Genes Chromosom Cancer. 2021;60(5):314\u201331.","journal-title":"Genes Chromosom Cancer"},{"issue":"7793","key":"1060_CR36","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41586-020-1943-3","volume":"578","author":"LB Alexandrov","year":"2020","unstructured":"Alexandrov LB, Kim J, Haradhvala NJ, Huang MN, Tian Ng AW, Wu Y, et al. The repertoire of mutational signatures in human cancer. Nature. 2020;578(7793):94\u2013101.","journal-title":"Nature."},{"issue":"4","key":"1060_CR37","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/nm.4292","volume":"23","author":"H Davies","year":"2017","unstructured":"Davies H, Glodzik D, Morganella S, Yates LR, Staaf J, Zou X, et al. HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures. Nat Med. 2017;23(4):517\u201325.","journal-title":"Nat Med"},{"issue":"15","key":"1060_CR38","doi-asserted-by":"publisher","first-page":"3764","DOI":"10.1158\/1078-0432.CCR-15-2477","volume":"22","author":"ML Telli","year":"2016","unstructured":"Telli ML, Timms KM, Reid J, Hennessy B, Mills GB, Jensen KC, et al. Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer. Clin Cancer Res. 2016;22(15):3764\u201373.","journal-title":"Clin Cancer Res"},{"key":"1060_CR39","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13059-016-0893-4","volume":"17","author":"R Rosenthal","year":"2016","unstructured":"Rosenthal R, McGranahan N, Herrero J, Taylor BS, Swanton C. DeconstructSigs: delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution. Genome Biol. 2016;17:31.","journal-title":"Genome Biol"},{"issue":"1","key":"1060_CR40","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1093\/annonc\/mdu479","volume":"26","author":"F Favero","year":"2015","unstructured":"Favero F, Joshi T, Marquard AM, Birkbak NJ, Krzystanek M, Li Q, et al. Sequenza: allele-specific copy number and mutation profiles from tumor sequencing data. Ann Oncol. 2015;26(1):64\u201370.","journal-title":"Ann Oncol"},{"key":"1060_CR41","unstructured":"Holmes O, Xu Q, Leonard C, Newell F, Wood S, Waddell N, Pearson JV. qsignature. Github. https:\/\/github.com\/AdamaJava\/adamajava\/tree\/master\/qsignature. Cited 13 May 2022."},{"issue":"23","key":"1060_CR42","doi-asserted-by":"publisher","first-page":"3310","DOI":"10.1093\/bioinformatics\/btu548","volume":"30","author":"A Szolek","year":"2014","unstructured":"Szolek A, Schubert B, Mohr C, Sturm M, Feldhahn M, Kohlbacher O. OptiType: precision HLA typing from next-generation sequencing data. Bioinformatics. 2014;30(23):3310\u20136.","journal-title":"Bioinformatics."},{"issue":"1","key":"1060_CR43","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s13059-016-0974-4","volume":"17","author":"W McLaren","year":"2016","unstructured":"McLaren W, Gil L, Hunt SE, Riat HS, Ritchie GRS, Thormann A, et al. The Ensembl variant effect predictor. Genome Biol. 2016;17(1):122.","journal-title":"Genome Biol"},{"issue":"1","key":"1060_CR44","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s13073-016-0264-5","volume":"8","author":"J Hundal","year":"2016","unstructured":"Hundal J, Carreno BM, Petti AA, Linette GP, Griffith OL, Mardis ER, et al. pVAC-Seq: A genome-guided in silico approach to identifying tumor neoantigens. Genome Med. 2016;8(1):11.","journal-title":"Genome Med"},{"issue":"9","key":"1060_CR45","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.4049\/jimmunol.1700893","volume":"199","author":"V Jurtz","year":"2017","unstructured":"Jurtz V, Paul S, Andreatta M, Marcatili P, Peters B, Nielsen M. NetMHCpan-4.0: improved peptide\u2013MHC class I interaction predictions integrating eluted ligand and peptide binding affinity data. J Immunol. 2017;199(9):3360.","journal-title":"J Immunol"},{"key":"1060_CR46","unstructured":"Holmes O, Xu Q, Leonard C, Newell F, Wood S, Waddell N, Pearson JV. qbasepileup. Github. https:\/\/github.com\/AdamaJava\/adamajava\/tree\/master\/qbasepileup. Cited 13 May 2022."},{"issue":"1","key":"1060_CR47","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1186\/s13059-019-1842-9","volume":"20","author":"BJ Haas","year":"2019","unstructured":"Haas BJ, Dobin A, Li B, Stransky N, Pochet N, Regev A. Accuracy assessment of fusion transcript detection via read-mapping and de novo fusion transcript assembly-based methods. Genome Biol. 2019;20(1):213.","journal-title":"Genome Biol"},{"key":"1060_CR48","doi-asserted-by":"publisher","unstructured":"Murphy C, Elemento O. AGFusion: annotate and visualize gene fusions. bioRxiv. 2016. https:\/\/doi.org\/10.1101\/080903.","DOI":"10.1101\/080903"},{"issue":"1","key":"1060_CR49","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29(1):15\u201321.","journal-title":"Bioinformatics."},{"key":"1060_CR50","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1186\/1471-2105-12-323","volume":"12","author":"B Li","year":"2011","unstructured":"Li B, Dewey CN. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics. 2011;12:323.","journal-title":"BMC Bioinformatics"},{"issue":"5","key":"1060_CR51","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nmeth.3337","volume":"12","author":"AM Newman","year":"2015","unstructured":"Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12(5):453\u20137.","journal-title":"Nat Methods"},{"issue":"1","key":"1060_CR52","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.cell.2014.12.033","volume":"160","author":"S Rooney Michael","year":"2015","unstructured":"Rooney Michael S, Shukla Sachet A, Wu Catherine J, Getz G, Hacohen N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell. 2015;160(1):48\u201361.","journal-title":"Cell."},{"issue":"7605","key":"1060_CR53","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nature17676","volume":"534","author":"S Nik-Zainal","year":"2016","unstructured":"Nik-Zainal S, Davies H, Staaf J, Ramakrishna M, Glodzik D, Zou X, et al. Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature. 2016;534(7605):47\u201354.","journal-title":"Nature."},{"issue":"7540","key":"1060_CR54","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nature14169","volume":"518","author":"N Waddell","year":"2015","unstructured":"Waddell N, Pajic M, Patch AM, Chang DK, Kassahn KS, Bailey P, et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature. 2015;518(7540):495\u2013501.","journal-title":"Nature."},{"issue":"6","key":"1060_CR55","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/ng.3287","volume":"47","author":"RD Weren","year":"2015","unstructured":"Weren RD, Ligtenberg MJ, Kets CM, de Voer RM, Verwiel ET, Spruijt L, et al. A germline homozygous mutation in the base-excision repair gene NTHL1 causes adenomatous polyposis and colorectal cancer. Nat Genet. 2015;47(6):668\u201371.","journal-title":"Nat Genet"},{"issue":"69","key":"1060_CR56","doi-asserted-by":"publisher","first-page":"113673","DOI":"10.18632\/oncotarget.22817","volume":"8","author":"M Hylebos","year":"2017","unstructured":"Hylebos M, Van Camp G, Vandeweyer G, Fransen E, Beyens M, Cornelissen R, et al. Large-scale copy number analysis reveals variations in genes not previously associated with malignant pleural mesothelioma. Oncotarget. 2017;8(69):113673\u201386.","journal-title":"Oncotarget."},{"issue":"6","key":"1060_CR57","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1002\/1878-0261.12651","volume":"14","author":"L Quetel","year":"2020","unstructured":"Quetel L, Meiller C, Assie JB, Blum Y, Imbeaud S, Montagne F, et al. Genetic alterations of malignant pleural mesothelioma: association with tumor heterogeneity and overall survival. Mol Oncol. 2020;14(6):1207\u201323.","journal-title":"Mol Oncol"},{"issue":"28","key":"1060_CR58","doi-asserted-by":"publisher","first-page":"3748","DOI":"10.1038\/onc.2013.351","volume":"33","author":"A Tallet","year":"2014","unstructured":"Tallet A, Nault JC, Renier A, Hysi I, Galateau-Salle F, Cazes A, et al. Overexpression and promoter mutation of the TERT gene in malignant pleural mesothelioma. Oncogene. 2014;33(28):3748\u201352.","journal-title":"Oncogene."},{"issue":"8","key":"1060_CR59","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/S1470-2045(17)30516-8","volume":"18","author":"S Turajlic","year":"2017","unstructured":"Turajlic S, Litchfield K, Xu H, Rosenthal R, McGranahan N, Reading JL, et al. Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis. Lancet Oncol. 2017;18(8):1009\u201321.","journal-title":"Lancet Oncol"},{"issue":"15","key":"1060_CR60","first-page":"3200","volume":"57","author":"AL Marzo","year":"1997","unstructured":"Marzo AL, Fitzpatrick DR, Robinson BW, Scott B. Antisense oligonucleotides specific for transforming growth factor beta2 inhibit the growth of malignant mesothelioma both in vitro and in vivo. Cancer Res. 1997;57(15):3200\u20137.","journal-title":"Cancer Res"},{"issue":"3","key":"1060_CR61","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1136\/thorax.58.3.198","volume":"58","author":"Z Liu","year":"2003","unstructured":"Liu Z, Klominek J. Regulation of matrix metalloprotease activity in malignant mesothelioma cell lines by growth factors. Thorax. 2003;58(3):198\u2013203.","journal-title":"Thorax."},{"issue":"1","key":"1060_CR62","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.jtho.2017.09.1968","volume":"13","author":"NS Patil","year":"2018","unstructured":"Patil NS, Righi L, Koeppen H, Zou W, Izzo S, Grosso F, et al. Molecular and histopathological characterization of the tumor immune microenvironment in advanced stage of malignant pleural mesothelioma. J Thorac Oncol. 2018;13(1):124\u201333.","journal-title":"J Thorac Oncol"},{"issue":"1","key":"1060_CR63","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13073-019-0620-3","volume":"11","author":"R Shrestha","year":"2019","unstructured":"Shrestha R, Nabavi N, Lin YY, Mo F, Anderson S, Volik S, et al. BAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesothelioma. Genome Med. 2019;11(1):8.","journal-title":"Genome Med"},{"issue":"1","key":"1060_CR64","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1038\/s41467-021-21798-w","volume":"12","author":"M Zhang","year":"2021","unstructured":"Zhang M, Luo JL, Sun Q, Harber J, Dawson AG, Nakas A, et al. Clonal architecture in mesothelioma is prognostic and shapes the tumour microenvironment. Nat Commun. 2021;12(1):1751.","journal-title":"Nat Commun"},{"issue":"8","key":"1060_CR65","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/S1470-2045(11)70149-8","volume":"12","author":"T Treasure","year":"2011","unstructured":"Treasure T, Lang-Lazdunski L, Waller D, Bliss JM, Tan C, Entwisle J, et al. Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncol. 2011;12(8):763\u201372.","journal-title":"Lancet Oncol"},{"issue":"1","key":"1060_CR66","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1097\/PAT.0b013e32835bc848","volume":"45","author":"A Segal","year":"2013","unstructured":"Segal A, Sterrett GF, Frost FA, Shilkin KB, Olsen NJ, Musk AW, et al. A diagnosis of malignant pleural mesothelioma can be made by effusion cytology: results of a 20 year audit. Pathology. 2013;45(1):44\u20138.","journal-title":"Pathology."},{"issue":"7463","key":"1060_CR67","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nature12477","volume":"500","author":"LB Alexandrov","year":"2013","unstructured":"Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, et al. Signatures of mutational processes in human cancer. Nature. 2013;500(7463):415\u201321.","journal-title":"Nature."},{"issue":"7","key":"1060_CR68","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/ng.855","volume":"43","author":"M Bott","year":"2011","unstructured":"Bott M, Brevet M, Taylor BS, Shimizu S, Ito T, Wang L, et al. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet. 2011;43(7):668\u201372.","journal-title":"Nat Genet"},{"issue":"1","key":"1060_CR69","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s12885-019-5314-0","volume":"19","author":"S Borchert","year":"2019","unstructured":"Borchert S, Wessolly M, Schmeller J, Mairinger E, Kollmeier J, Hager T, et al. Gene expression profiling of homologous recombination repair pathway indicates susceptibility for olaparib treatment in malignant pleural mesothelioma in vitro. BMC Cancer. 2019;19(1):108.","journal-title":"BMC Cancer"},{"key":"1060_CR70","doi-asserted-by":"crossref","unstructured":"Fennell DA, King A, Mohammed S, Branson A, Brookes C, Darlison L, et al. Rucaparib in patients with BAP1-deficient or BRCA1-deficient mesothelioma (MiST1): an open-label, single-arm, phase 2a clinical trial. Lancet Respir Med. 2021;9(6):593\u2013600.","DOI":"10.1016\/S2213-2600(20)30390-8"},{"issue":"10","key":"1060_CR71","volume":"2","author":"A Ghafoor","year":"2021","unstructured":"Ghafoor A, Mian I, Wagner C, Mallory Y, Agra MG, Morrow B, et al. Phase 2 study of olaparib in malignant mesothelioma and correlation of efficacy with germline or somatic mutations in BAP1 gene. JTO Clin Res Rep. 2021;2(10):100231.","journal-title":"JTO Clin Res Rep"},{"issue":"2","key":"1060_CR72","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.jtho.2018.10.001","volume":"14","author":"AS Mansfield","year":"2019","unstructured":"Mansfield AS, Peikert T, Smadbeck JB, Udell JBM, Garcia-Rivera E, Elsbernd L, et al. Neoantigenic potential of complex chromosomal rearrangements in mesothelioma. J Thorac Oncol. 2019;14(2):276\u201387.","journal-title":"J Thorac Oncol"},{"issue":"2","key":"1060_CR73","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.neo.2018.12.006","volume":"21","author":"S Bihr","year":"2019","unstructured":"Bihr S, Ohashi R, Moore AL, Ruschoff JH, Beisel C, Hermanns T, et al. Expression and mutation patterns of PBRM1, BAP1 and SETD2 mirror specific evolutionary subtypes in clear cell renal cell carcinoma. Neoplasia. 2019;21(2):247\u201356.","journal-title":"Neoplasia."},{"issue":"1","key":"1060_CR74","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1038\/s41467-019-09241-7","volume":"10","author":"Y Huang","year":"2019","unstructured":"Huang Y, Wang J, Jia P, Li X, Pei G, Wang C, et al. Clonal architectures predict clinical outcome in clear cell renal cell carcinoma. Nat Commun. 2019;10(1):1245.","journal-title":"Nat Commun"},{"issue":"6377","key":"1060_CR75","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1126\/science.aan5951","volume":"359","author":"D Miao","year":"2018","unstructured":"Miao D, Margolis CA, Gao W, Voss MH, Li W, Martini DJ, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801\u20136.","journal-title":"Science."},{"issue":"1","key":"1060_CR76","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13073-019-0631-0","volume":"11","author":"M Ladanyi","year":"2019","unstructured":"Ladanyi M, Sanchez Vega F, Zauderer M. Loss of BAP1 as a candidate predictive biomarker for immunotherapy of mesothelioma. Genome Med. 2019;11(1):18.","journal-title":"Genome Med"},{"issue":"1","key":"1060_CR77","doi-asserted-by":"publisher","first-page":"20059","DOI":"10.1038\/s41598-021-99524-1","volume":"11","author":"SI Gutiontov","year":"2021","unstructured":"Gutiontov SI, Turchan WT, Spurr LF, Rouhani SJ, Chervin CS, Steinhardt G, et al. CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer. Sci Rep. 2021;11(1):20059.","journal-title":"Sci Rep"},{"issue":"5","key":"1060_CR78","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.semcancer.2008.03.004","volume":"18","author":"A Sica","year":"2008","unstructured":"Sica A, Larghi P, Mancino A, Rubino L, Porta C, Totaro MG, et al. Macrophage polarization in tumour progression. Semin Cancer Biol. 2008;18(5):349\u201355.","journal-title":"Semin Cancer Biol"},{"issue":"1","key":"1060_CR79","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00428-018-2461-7","volume":"474","author":"M Heiskala","year":"2019","unstructured":"Heiskala M, Leidenius M, Joensuu K, Heikkila P. High expression of CCL2 in tumor cells and abundant infiltration with CD14 positive macrophages predict early relapse in breast cancer. Virchows Arch. 2019;474(1):3\u201312.","journal-title":"Virchows Arch"},{"issue":"10","key":"1060_CR80","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1016\/j.jtho.2016.06.022","volume":"11","author":"AL Chene","year":"2016","unstructured":"Chene AL, d'Almeida S, Blondy T, Tabiasco J, Deshayes S, Fonteneau JF, et al. Pleural effusions from patients with mesothelioma induce recruitment of monocytes and their differentiation into M2 macrophages. J Thorac Oncol. 2016;11(10):1765\u201373.","journal-title":"J Thorac Oncol"},{"issue":"32","key":"1060_CR81","doi-asserted-by":"publisher","first-page":"52294","DOI":"10.18632\/oncotarget.10561","volume":"7","author":"F Zhang","year":"2016","unstructured":"Zhang F, Wang H, Wang X, Jiang G, Liu H, Zhang G, et al. TGF-beta induces M2-like macrophage polarization via SNAIL-mediated suppression of a pro-inflammatory phenotype. Oncotarget. 2016;7(32):52294\u2013306.","journal-title":"Oncotarget."},{"key":"1060_CR82","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.lungcan.2019.11.013","volume":"139","author":"P Stockhammer","year":"2020","unstructured":"Stockhammer P, Ploenes T, Theegarten D, Schuler M, Maier S, Aigner C, et al. Detection of TGF-beta in pleural effusions for diagnosis and prognostic stratification of malignant pleural mesothelioma. Lung Cancer. 2020;139:124\u201332.","journal-title":"Lung Cancer"},{"issue":"1","key":"1060_CR83","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s12964-020-00589-8","volume":"18","author":"Q Hao","year":"2020","unstructured":"Hao Q, Vadgama JV, Wang P. CCL2\/CCR2 signaling in cancer pathogenesis. Cell Commun Signal. 2020;18(1):82.","journal-title":"Cell Commun Signal"},{"key":"1060_CR84","doi-asserted-by":"crossref","unstructured":"Huynh LK, Hipolito CJ, Ten Dijke P. A perspective on the development of TGF-beta inhibitors for cancer treatment. Biomolecules. 2019;9(11):743","DOI":"10.3390\/biom9110743"},{"issue":"8","key":"1060_CR85","doi-asserted-by":"publisher","DOI":"10.4161\/onci.26218","volume":"2","author":"JP Stevenson","year":"2013","unstructured":"Stevenson JP, Kindler HL, Papasavvas E, Sun J, Jacobs-Small M, Hull J, et al. Immunological effects of the TGFbeta-blocking antibody GC1008 in malignant pleural mesothelioma patients. Oncoimmunology. 2013;2(8):e26218.","journal-title":"Oncoimmunology."},{"issue":"1","key":"1060_CR86","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s12943-019-1055-6","volume":"18","author":"M Peng","year":"2019","unstructured":"Peng M, Mo Y, Wang Y, Wu P, Zhang Y, Xiong F, et al. Neoantigen vaccine: an emerging tumor immunotherapy. Mol Cancer. 2019;18(1):128.","journal-title":"Mol Cancer"},{"key":"1060_CR87","unstructured":"Creaney J, Patch AM, Addala V, Pearson JV, Robinson BW, Waddell N. Whole genome sequence and RNA-seq data from paired tumour and germline samples from mesothelioma patients. EGAS00001005196, European Genome-Phenome Archive. 2022; https:\/\/ega-archive.org\/studies\/EGAS00001005196."}],"container-title":["Genome Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13073-022-01060-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13073-022-01060-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13073-022-01060-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,30]],"date-time":"2022-05-30T04:08:12Z","timestamp":1653883692000},"score":1,"resource":{"primary":{"URL":"https:\/\/genomemedicine.biomedcentral.com\/articles\/10.1186\/s13073-022-01060-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,30]]},"references-count":87,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1060"],"URL":"https:\/\/doi.org\/10.1186\/s13073-022-01060-8","relation":{},"ISSN":["1756-994X"],"issn-type":[{"value":"1756-994X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,30]]},"assertion":[{"value":"18 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All patients provided written informed consent to participate in this study with approval of the Dana-Farber Brigham and Women\u2019s Cancer Center Institutional Review Board (Boston, MA, USA), University Hospitals of Leicester National Health Service Trust (Leicester, UK) and the Sir Charles Gairdner and Osborne Park Hospital Research Ethics Committee (SCGOPH REC; Perth, Western Australia, Australia). The study was approved by the Sir Charles Gairdner and Osborne Park Hospital Research Ethics Committee (RGS0000001517). The WGS analysis was conducted at QIMR Berghofer with approval from the QIMR Berghofer Research Ethics Committee (P3521). The research in this manuscript conforms to the principles of the Helsinki Declaration.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All patients provided written informed consent for the study and consented to publishing all patient-related data included in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JV Pearson and N Waddell are founders of genomiQa Pty Ltd, and members of the genomiQa Board. The remaining authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"58"}}